[Click eStock] "JLK, Time for Valuation Reassessment"

Hanyang Securities analyzed on the 21st that it is a time to reassess the valuation of JLK. No investment opinion or target price was presented.

Lee Jun-seok, a researcher at Hanyang Securities, stated, "JLK is the company with the most U.S. Food and Drug Administration (FDA) approvals and applications for artificial intelligence (AI) stroke solutions in Korea, actively targeting entry into the U.S. market. It has already exceeded expectations by achieving a total of three approvals, surpassing the initial goal of one approval set earlier this year."

He added, "In the context of recovering sentiment toward medical AI companies, it is time to reassess JLK's valuation as it aggressively pursues FDA approvals while delivering successful results."

He also advised paying close attention to the International Stroke Conference (ISC) to be held in Los Angeles, USA, from February 5 to 7 next year. He explained, "JLK is scheduled to present a research abstract at ISC 2025 on the topic utilizing JLK-DWI. Through this academic conference, JLK plans to actively promote the adoption of its AI stroke solutions and establish a foundation for global expansion, including the U.S., aiming to generate future revenue."

In particular, the first half of next year is expected, according to the researcher. He emphasized, "The three solutions that received FDA 510(k) approval this year are expected to obtain NTAP approval from the U.S. Centers for Medicare & Medicaid Services (CMS) in the first half of next year, leading to contracts with U.S. private insurers and medical device companies. Additionally, FDA 510(k) approval results for AI stroke solutions already applied for will be announced in the first half of next year, with plans for one to two additional applications."

He stressed, "Although the U.S. market entry is becoming more concrete, the stock price remains at its lowest level of the year. With figures like Elon Musk also highlighting the importance of AI medical diagnostics, interest and paradigms regarding medical AI in the U.S. are changing, raising expectations for the company's future trajectory."